What's Happening?
Lantern Pharma has received a positive response from the FDA regarding its Type C meeting request for the HARMONIC™ Phase 2 trial of LP-300, targeting never-smokers with advanced non-small cell lung cancer (NSCLC). The FDA raised no objections to key
protocol amendments, including focusing enrollment on patients with EGFR exon 21 L858R mutations, extending LP-300 dosing to eight cycles, and transitioning to a single-arm study design. These changes aim to provide a clearer regulatory path and support the development of LP-300 for this high-need patient population. The trial is designed to evaluate LP-300 in combination with carboplatin and pemetrexed, offering potential benefits for patients who have experienced disease progression following treatment with kinase inhibitors.
Why It's Important?
The FDA's support for the HARMONIC™ trial is a significant milestone for Lantern Pharma, as it provides a more focused regulatory path for developing LP-300. This trial targets a distinct subset of NSCLC patients who have limited treatment options and often experience inferior outcomes with current therapies. By focusing on the EGFR exon 21 L858R mutation, the trial aims to address a critical unmet need in cancer treatment. The success of this trial could lead to new therapeutic options for never-smokers with NSCLC, potentially improving outcomes for a large patient population globally.
What's Next?
Lantern Pharma plans to continue enrolling patients in the HARMONIC™ trial, focusing on those with the EGFR exon 21 L858R mutation. The company aims to generate a more focused data set to support discussions with regulators and potential partners. The trial's progress and emerging data will be closely monitored, with additional updates expected in the second half of 2026. Lantern is also exploring collaboration opportunities to maximize the commercial potential of LP-300 across various regions, particularly where never-smoker NSCLC is a significant clinical challenge.
